Drugs score big wins against lung, prostate, breast cancers

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

CHICAGO (AP) _ Drugs are scoring big wins against common cancers, setting new standards for treating prostate, breast and lung tumors. Most striking is that some are giving benefit well past a year, much longer than the few months many new drugs offer.

Studies suggest the drug Zytiga (zye-TEE-guh) will become a first-treatment choice for men whose prostate cancer has spread.

For advanced lung cancer with a certain gene flaw, the drug Alecensa (al-uh-SEN-suh) stopped cancer growth for 15 months longer than a drug used now called Xalkori (zal-KOR-ee).

For women with a gene that raises their risk for breast cancer, a relatively new drug called Lynparza (lin-PAR-zuh) showed promise.

Results are being discussed Monday at a cancer conference in Chicago.